Subscribe To
HOOKIPA Pharma Reports Second Quarter 2023 Financial Results and Recent Business Highlights
HOOKIPA reported positive preliminary Phase 2 data on HB-200 in combination with pembrolizumab in 1st-line setting for advanced head and neck cancer Recruitment ongoing for two Phase 1 clinical trials (HB-300 for advanced prostate cancer and Gilead-partnered HB-400 for chronic hepatitis B) IND-enabling activities in progress to advance two additional therapeutics into the clinic in […] The post HOOKIPA Pharma Reports Second Quarter 2023 Financial Results and Recent Business Highlights appeared f...
Read More
Posted: Aug 10 2023, 11:01
Author Name: forextv
Views: 092062